Optimization of a Self-microemulsifying Drug Delivery System for Oral Administration of the Lipophilic Drug, Resveratrol: Enhanced Intestinal Permeability in Rat

Purpose: This study aimed to formulate Resveratrol, a practically water-insoluble antioxidant in a self-microemulsifying drug delivery system (SMEDDS) to improve the solubility, release rate, and intestinal permeability of the drug. Methods: The suitable oil, surfactant, and co-surfactant were chose...

Full description

Saved in:
Bibliographic Details
Published inAdvanced pharmaceutical bulletin Vol. 13; no. 3; pp. 521 - 531
Main Authors Mirzaeei, Shahla, Tahmasebi, Negar, Islambulchilar, Ziba
Format Journal Article
LanguageEnglish
Published Tabriz Tabriz University of Medical Sciences 01.07.2023
Subjects
Online AccessGet full text
ISSN2228-5881
2251-7308
DOI10.34172/apb.2023.054

Cover

Abstract Purpose: This study aimed to formulate Resveratrol, a practically water-insoluble antioxidant in a self-microemulsifying drug delivery system (SMEDDS) to improve the solubility, release rate, and intestinal permeability of the drug. Methods: The suitable oil, surfactant, and co-surfactant were chosen according to the drug solubility study. Utilizing the design of experiment (DoE) method, the pseudo-ternary phase diagram was plotted based on the droplet size. In vitro dissolution study and the single-pass intestinal perfusion were performed for the investigation of in vitro and in-situ permeability for drugs formulated as SMEDDS in rat intestine using High-Performance Liquid Chromatography. Results: Castor oil, Cremophor RH60, and PEG 1500 were selected as oil, surfactant, and co-surfactant. According to the pseudo-ternary phase diagram, nine formulations developed microemulsions with sizes ranging between 145-967 nm. Formulations passed the centrifuge and freeze-thaw stability tests. The optimum formulation possessed an almost 2.5-fold higher cumulative percentage of in vitro released resveratrol, in comparison to resveratrol aqueous suspension within 120 minutes. The results of the in-situ permeability study suggested a 2.6-fold higher intestinal permeability for optimum formulation than that of the resveratrol suspension. Conclusions: SMEDDS can be considered suitable for the oral delivery of resveratrol according to the observed increased intestinal permeability, which could consequently enhance the bioavailability and therapeutic efficacy of the drug.
AbstractList This study aimed to formulate Resveratrol, a practically water-insoluble antioxidant in a self-microemulsifying drug delivery system (SMEDDS) to improve the solubility, release rate, and intestinal permeability of the drug.PurposeThis study aimed to formulate Resveratrol, a practically water-insoluble antioxidant in a self-microemulsifying drug delivery system (SMEDDS) to improve the solubility, release rate, and intestinal permeability of the drug.The suitable oil, surfactant, and co-surfactant were chosen according to the drug solubility study. Utilizing the design of experiment (DoE) method, the pseudo-ternary phase diagram was plotted based on the droplet size. In vitro dissolution study and the single-pass intestinal perfusion were performed for the investigation of in vitro and in-situ permeability for drugs formulated as SMEDDS in rat intestine using High-Performance Liquid Chromatography.MethodsThe suitable oil, surfactant, and co-surfactant were chosen according to the drug solubility study. Utilizing the design of experiment (DoE) method, the pseudo-ternary phase diagram was plotted based on the droplet size. In vitro dissolution study and the single-pass intestinal perfusion were performed for the investigation of in vitro and in-situ permeability for drugs formulated as SMEDDS in rat intestine using High-Performance Liquid Chromatography.Castor oil, Cremophor® RH60, and PEG 1500 were selected as oil, surfactant, and co-surfactant. According to the pseudo-ternary phase diagram, nine formulations developed microemulsions with sizes ranging between 145-967 nm. Formulations passed the centrifuge and freeze-thaw stability tests. The optimum formulation possessed an almost 2.5-fold higher cumulative percentage of in vitro released resveratrol, in comparison to resveratrol aqueous suspension within 120 minutes. The results of the in-situ permeability study suggested a 2.6-fold higher intestinal permeability for optimum formulation than that of the resveratrol suspension.ResultsCastor oil, Cremophor® RH60, and PEG 1500 were selected as oil, surfactant, and co-surfactant. According to the pseudo-ternary phase diagram, nine formulations developed microemulsions with sizes ranging between 145-967 nm. Formulations passed the centrifuge and freeze-thaw stability tests. The optimum formulation possessed an almost 2.5-fold higher cumulative percentage of in vitro released resveratrol, in comparison to resveratrol aqueous suspension within 120 minutes. The results of the in-situ permeability study suggested a 2.6-fold higher intestinal permeability for optimum formulation than that of the resveratrol suspension.SMEDDS can be considered suitable for the oral delivery of resveratrol according to the observed increased intestinal permeability, which could consequently enhance the bioavailability and therapeutic efficacy of the drug.ConclusionSMEDDS can be considered suitable for the oral delivery of resveratrol according to the observed increased intestinal permeability, which could consequently enhance the bioavailability and therapeutic efficacy of the drug.
According to the pseudo-ternary phase diagram, nine formulations developed microemulsions with sizes ranging between 145-967 nm. Many drugs are constantly administered orally, and it is also one of the most cost-effective systems for production besides all advantages reported for it.1,2 Oral absorption greatly depends on the dissolution rate in the gastric fluids.3 Most of the drugs have poor water-solubility and hence poor bioavailability as a major challenge for oral delivery.4,5 This poor bioavailability resulted from the fact that a drug cannot be absorbed from the gastrointestinal tract until it becomes soluble in gastric fluid.6,7 The rate-limiting step for absorption of poorly soluble but easily permeable drugs belonging to class II of the biopharmaceutics classification system is their solubility in gastric fluids.8 Resveratrol is a water-insoluble,(aqueous solubility =0.03 mg/mL) class II drug which, as an antioxidant polyphenol, exists in grapes, peanuts, and berries.9 This drug has been the subject of interest in recent years because of its anticancer, anti-aging, anti-diabetic, and cardio-protective effects.1013 The low bioavailability of resveratrol following oral administration is due to its low solubility.14,15 Novel drug delivery systems are capable of enhancing the pharmacokinetic properties and bioavailability of the drug through different strategies.16 Micro- and nano-emulsions are promising systems for the delivery of hydrophobic drugs.17 Furthermore, one of the popular novel drug delivery systems is the self-microemulsifying drug delivery system (SMEDDS) which is an isotropic mixture of oil, surfactant, and co-surfactant.18 When the formulation is faced with gastric fluids, it is rapidly converted to an oil-in-water emulsion by gentle movements of gastrointestinal muscles, hence called self-emulsifying.19,20 SMEDDS promotes drug absorption by increasing the amount of drug dissolved in the intestinal fluid. To determine the most suitable components, according to the standard method,23 an excess amount of resveratrol was dissolved in 2 mL of different vehicles including castor oil, pomegranate seed oil, grape seed oil, liquid paraffin, olive oil, medium-chain triglyceride, soybean oil, glycerol, ethyl oleate, sesame oil, and sunflower oil as the candidates for oil phase, and PEG,"", PEG,"", PEGm", PEG,m", and PG as 1 zUU 4UU 6UU 1SUU co-surfactants, and tween 20, tween 80, and Cremophor RH60 as surfactants. [...]samples were visually inspected for instability, and the size changes were evaluated by a zeta-sizer.
Purpose: This study aimed to formulate Resveratrol, a practically water-insoluble antioxidant in a self-microemulsifying drug delivery system (SMEDDS) to improve the solubility, release rate, and intestinal permeability of the drug. Methods: The suitable oil, surfactant, and co-surfactant were chosen according to the drug solubility study. Utilizing the design of experiment (DoE) method, the pseudo-ternary phase diagram was plotted based on the droplet size. In vitro dissolution study and the single-pass intestinal perfusion were performed for the investigation of in vitro and in-situ permeability for drugs formulated as SMEDDS in rat intestine using High-Performance Liquid Chromatography. Results: Castor oil, Cremophor RH60, and PEG 1500 were selected as oil, surfactant, and co-surfactant. According to the pseudo-ternary phase diagram, nine formulations developed microemulsions with sizes ranging between 145-967 nm. Formulations passed the centrifuge and freeze-thaw stability tests. The optimum formulation possessed an almost 2.5-fold higher cumulative percentage of in vitro released resveratrol, in comparison to resveratrol aqueous suspension within 120 minutes. The results of the in-situ permeability study suggested a 2.6-fold higher intestinal permeability for optimum formulation than that of the resveratrol suspension. Conclusions: SMEDDS can be considered suitable for the oral delivery of resveratrol according to the observed increased intestinal permeability, which could consequently enhance the bioavailability and therapeutic efficacy of the drug.
Author Mirzaeei, Shahla
Islambulchilar, Ziba
Tahmasebi, Negar
AuthorAffiliation 2 Pharmaceutical Sciences Research Centre, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
3 Student Research Committee, School of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran
4 Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
1 Nano Drug Delivery Research Centre, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
AuthorAffiliation_xml – name: 1 Nano Drug Delivery Research Centre, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
– name: 3 Student Research Committee, School of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran
– name: 2 Pharmaceutical Sciences Research Centre, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
– name: 4 Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
Author_xml – sequence: 1
  givenname: Shahla
  orcidid: 0000-0002-1132-3150
  surname: Mirzaeei
  fullname: Mirzaeei, Shahla
  organization: Nano Drug Delivery Research Centre, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran., Pharmaceutical Sciences Research Centre, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
– sequence: 2
  givenname: Negar
  orcidid: 0000-0001-6396-1456
  surname: Tahmasebi
  fullname: Tahmasebi, Negar
  organization: Student Research Committee, School of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran
– sequence: 3
  givenname: Ziba
  orcidid: 0000-0001-7037-4436
  surname: Islambulchilar
  fullname: Islambulchilar, Ziba
  organization: Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
BookMark eNptkkFvFCEYhiemJta1R-8kXjw4KwPMwHgxTa26ySZrWj0Thvlml4aBEZgm67_xn8ruVpM2XoDA-z7wfbwvizPnHRTF6wovKas4ea-mbkkwoUtcs2fFOSF1VXKKxdlhTURZC1G9KC5iNB1mjBNRtdV58XszJTOaXyoZ75AfkEK3YIdyNDp4GGcbzbA3bos-hTkPYM09hD263ccEIxp8QJugLLrsR-NMTOEfJ-0Arc3kp52xRh_t79ANxGxXKXj7AV27nXIaerRyCWIyLnO-QRhBddmS9sg4dKPSq-L5oGyEi4d5Ufz4fP396mu53nxZXV2uS83qNpXNoDEjmoASQrGGKMxbSkWNVYV5VQNv-0GLrmcN4IbyrheN6JXqKOe0VYLSRbE6cXuv7uQUzKjCXnpl5HHDh61UIRltQWaErhRpOoUFEz3tAKuOUaxbDkPPRWZ9PLGmuRuh1-ByZ-wj6OMTZ3Zy6-9lhVmDRdVkwtsHQvA_59weOZqowVrlwM9RElGLtmWHIhfFmyfSOz-H3M2DijHc8IayrKInVf7XGAMMUpt0_K38AGPzzfKYI5lzJA85kjlH2VU-cf2t4f_6Pw93z3M
CitedBy_id crossref_primary_10_1080_20415990_2024_2363635
crossref_primary_10_2147_IJN_S472287
crossref_primary_10_1007_s12247_025_09924_3
crossref_primary_10_2174_2211738511666230112123235
ContentType Journal Article
Copyright 2023. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2023 The Authors.
2023 The Authors. 2023
Copyright_xml – notice: 2023. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2023 The Authors.
– notice: 2023 The Authors. 2023
DBID AAYXX
CITATION
8AO
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
CWDGH
DWQXO
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
7X8
5PM
DOA
DOI 10.34172/apb.2023.054
DatabaseName CrossRef
ProQuest Pharma Collection
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
Middle East & Africa Database
ProQuest Central Korea
Proquest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Pharma Collection
ProQuest Central
Middle East & Africa Database
ProQuest One Academic UKI Edition
ProQuest Central Korea
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
Publicly Available Content Database

CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 2251-7308
EndPage 531
ExternalDocumentID oai_doaj_org_article_6e0c1a26ba0848d3be0ab430c97efd78
PMC10460816
10_34172_apb_2023_054
Genre General Information
GeographicLocations Germany
GeographicLocations_xml – name: Germany
GroupedDBID 5VS
8AO
AAYXX
ABDBF
ABUWG
ACUHS
ADBBV
AEGXH
AFKRA
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
BENPR
BPHCQ
CCPQU
CITATION
CWDGH
DIK
EOJEC
GROUPED_DOAJ
GX1
HYE
KQ8
OBODZ
OK1
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
RNS
RPM
TUS
AZQEC
DWQXO
PKEHL
PQEST
PQUKI
7X8
M~E
5PM
PUEGO
ID FETCH-LOGICAL-c459t-6fc042c2ea88a462a07933850a10715e79dfc8bd46e0637bd868daab37739a833
IEDL.DBID BENPR
ISSN 2228-5881
IngestDate Wed Aug 27 00:56:19 EDT 2025
Thu Aug 21 18:36:26 EDT 2025
Mon Jul 21 10:28:02 EDT 2025
Mon Jun 30 03:17:04 EDT 2025
Tue Jul 01 04:25:25 EDT 2025
Thu Apr 24 23:10:46 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c459t-6fc042c2ea88a462a07933850a10715e79dfc8bd46e0637bd868daab37739a833
Notes SourceType-Scholarly Journals-1
ObjectType-General Information-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0001-6396-1456
0000-0002-1132-3150
0000-0001-7037-4436
OpenAccessLink https://www.proquest.com/docview/2844067634?pq-origsite=%requestingapplication%
PQID 2844067634
PQPubID 2032008
PageCount 11
ParticipantIDs doaj_primary_oai_doaj_org_article_6e0c1a26ba0848d3be0ab430c97efd78
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10460816
proquest_miscellaneous_2858994079
proquest_journals_2844067634
crossref_citationtrail_10_34172_apb_2023_054
crossref_primary_10_34172_apb_2023_054
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20230701
PublicationDateYYYYMMDD 2023-07-01
PublicationDate_xml – month: 07
  year: 2023
  text: 20230701
  day: 01
PublicationDecade 2020
PublicationPlace Tabriz
PublicationPlace_xml – name: Tabriz
PublicationTitle Advanced pharmaceutical bulletin
PublicationYear 2023
Publisher Tabriz University of Medical Sciences
Publisher_xml – name: Tabriz University of Medical Sciences
SSID ssib044728191
ssj0000603415
Score 2.28262
Snippet Purpose: This study aimed to formulate Resveratrol, a practically water-insoluble antioxidant in a self-microemulsifying drug delivery system (SMEDDS) to...
According to the pseudo-ternary phase diagram, nine formulations developed microemulsions with sizes ranging between 145-967 nm. Many drugs are constantly...
This study aimed to formulate Resveratrol, a practically water-insoluble antioxidant in a self-microemulsifying drug delivery system (SMEDDS) to improve the...
SourceID doaj
pubmedcentral
proquest
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 521
SubjectTerms antioxidant
Antioxidants
Bioavailability
Design of experiments
Drug delivery systems
Drugs
intestinal permeability
Microemulsions
Oral administration
oral drug delivery
Permeability
Polyethylene glycol
resveratrol
self-micro emulsifying drug delivery systems
single-pass intestinal perfusion
Software
Surfactants
Vegetable oils
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQT1wQT7FQKiOhPW1aJ3YchxuPVhUCuiqt1Jvlp7pSNlntA2l_Tv8pM0m63RwQFy452E5ie8bjGXvmG0I-xJjmjouQZLnniYjKJcYUZQI7twMNNTph8Ub3x095fi2-3eQ3e6m-0CesgwfuJu5EBuZSk0lrEPndcxuYsYIzVxYh-qIN82Ul2zOmgJOEKPCCKN2dtjDJQFyjPyOeeCS5UmkHuAmlRXZiFvYY84gfs1wMNqgWx3-gfA5dJ_f2orOn5EmvRNJPXeefkUehfk7G0w6FejuhVw9BVasJHdPpAz719gW5uwAxMe_jL2kTqaG_QhWTOfrmhfmmWs3a4Cf6dbmBR6jQdWNLO2xzCkouvVji3wewu_gd0CXp99miWeAhjWtfn9DLsPqNwM3LpvpIT-vb1uOA4kEkCBccxRT2htChhW_prKaXZv2SXJ-dXn05T_pMDYkTeblOgKaw-F0WjFJGyMwg7B5XOTNgXaZ5KEofnbJeADUlL6xXUnljLC8KXhrF-StyUDd1eE2osE4EJYXxIgrBI4LnZNZ4ixG0TtoRmdyTR7sexhyzaVQazJmWmhqoqZGaGqg5IuNd80WH3_G3hp-R1rtGCLvdFgAz6p4Z9b-YcUQO7zlF97JgpUEBAK0J5Dj84_2uGlYxXs2YOjQbbJOD4QvGdTkiasBhgw4Na-rZbYsHjtf0mD_lzf8YwlvyGKek80g-JAfr5Sa8A71rbY_aJfYHFmot-A
  priority: 102
  providerName: Directory of Open Access Journals
Title Optimization of a Self-microemulsifying Drug Delivery System for Oral Administration of the Lipophilic Drug, Resveratrol: Enhanced Intestinal Permeability in Rat
URI https://www.proquest.com/docview/2844067634
https://www.proquest.com/docview/2858994079
https://pubmed.ncbi.nlm.nih.gov/PMC10460816
https://doaj.org/article/6e0c1a26ba0848d3be0ab430c97efd78
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9NAEF5Be-GCeApDqRYJ5RS3fqztdS-IQqoK0TYKrdSbtS-3kRzb2EmlXPgv_FNm7E2CD3DxwV6_NLPfzM7MfkPIxzz3IxUy4waRDl2Wc-UKkaQuWG4FHmqumMSM7sVlfH7Dvt1Gtzbg1tqyyg0mdkCtK4Ux8mOAUbA9MBvYp_qni12jMLtqW2g8JvsAwRz0fP90cjmdbTSKsQQTRf426uLFHsA21jVi5MONOPd74k04mwTHopZH2E_8yIvYwFB1fP4DJ3RYQvmXTTp7Rp5aZ5J-7qX_nDwy5QsymvZs1Osxvd5trmrHdESnO57q9Uvy-wrgYmH3YdIqp4L-MEXuLrBGzyxWRTvvNkHRr80KDqbAEo417TnOKTi79KrBtw_od_E54FPS7_O6qjFYo7rbx3Rm2gckcG6q4oROyvuu8oBiQBJABv9iCjbC9Kzhazov6UwsX5Gbs8n1l3PXdmxwFYvSpQuyBRBQgRGcCxYHAun3Qh55AlaZfmSSVOeKS81iA65RIjWPuRZChkkSpoKH4WuyV1aleUMok4oZHjOhWc5YmCOJTiCFlriTVsXSIeONeDJl6cyxq0aRwbKmk2YG0sxQmhlI0yGj7fC65_H418BTlPV2ENJvdyeq5i6zszmDz1e-CGIpsB2BDqXxhGShp9LE5DrhDjnYaEpmMaHNdhrskA_byzCbMUUjSlOtcEwEC2BYZKcO4QMNG3zQ8Eo5v-94wTFdj31U3v7_7e_IE_zZvub4gOwtm5V5D57VUh7a6XPYRSbgePFr8gemmihA
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF5V6QEuiKcIFFgkyClu_VjbaySEKE2V0jSNQir1ZnbXuzRSYoc8QP45_AF-IzN-JPgAt158sNfetWZ2XjvzDSFvjHF85TFtuX7iWcxwZQkRRhZobgUWqlFM4onuxTDoX7HP1_71Hvld18JgWmUtEwtBnWQKY-RHIEZB98BuYB8W3y3sGoWnq3ULjZItznX-E1y21fuzE6DvW9c97U0-9a2qq4ClmB-tLZgfGFW5WnAuWOAKhIjzuG8L8IQcX4dRYhSXCQs0qO9QJjzgiRDSC0MvEhwDoCDy9xlWtLbI_nFvOBrXHMxYiAdTzjbKYwc2qAnMo8RIi-Vz7pRAn3A3dI_EQh5i__JD22cNxVj0D2gYvc2Uzb904Ol9cq8yXunHktsekD2dPiSdUYl-nXfpZFfMterSDh3tcLHzR-TXJYineVX3STNDBf2iZ8aaY06gnm9mq2lRdEVPlhu46BmmjOS0xFSnYFzTyyXO3oD7xe-ADUsH00W2wOCQKl7v0rFe_UDA6GU2e0d76U2R6UAxAApCDf9iBDpJlyjlOZ2mdCzWj8nVrdDyCWmlWaqfEsqkYpoHTCTMMOYZBO1xpUgkVu6qQLZJtyZPrCr4dOziMYvBjSqoGQM1Y6RmDNRsk852-KLEDfnXwGOk9XYQwn0XN7Llt7iSHjEsXznCDaTA9geJJ7UtJPNsFYXaJCFvk4OaU-JKBq3i3Y5pk9fbxyA98EhIpDrb4BgfHG5w6qM24Q0Oayyo-SSd3hQ45JgegH1bnv1_9lfkTn9yMYgHZ8Pz5-Qu_niZ73xAWuvlRr8Aq24tX1ZbiZKvt717_wDeZWIn
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF5VqYS4IJ4iUGCRIKe4cey1vUZCiJJELS2pFVqpN3d3vUsjJXaIE1B-Dn-DX8eMHwk-wK2XHOx1vNa8Z2e-IeSNMX1PuUxbjpe4FjNcWUIEoQWWW4GHahSTeKL7ZewfX7LPV97VHvld98JgWWWtEwtFnWQKc-Q9UKNge0AaWM9UZRHRYPRh8d3CCVJ40lqP0yhZ5FRvfkL4lr8_GQCt3zrOaHjx6diqJgxYinnhyoK9ANMqRwvOBfMdgXBxLvdsAVFR39NBmBjFZcJ8DaY8kAn3eSKEdIPADQXHZCio__0AdsZaZP9oOI4mNTczFuAhVX-b8bF9G0wG1lRi1sXyOO-XoJ9wNXB6YiEPcZb5oe2xhpEsZgk0HOBm-eZf9nB0n9yrHFn6seS8B2RPpw9JJyqRsDdderFr7Mq7tEOjHUb25hH5dQ6qal71gNLMUEG_6pmx5lgfqOfrWT4tGrDoYLmGHz3D8pENLfHVKTja9HyJb29A_-L_gD9Lz6aLbIGJIlU83qUTnf9A8OhlNntHh-lNUfVAMRkKCg6_IgL7pEvE8g2dpnQiVo_J5a3Q8glppVmqnxLKpGKa-0wkzDDmGgTwcaRIJHbxKl-2SbcmT6wqKHWc6DGLIaQqqBkDNWOkZgzUbJPOdvmixBD518IjpPV2EUJ_Fxey5be40iQxbF_1heNLgaMQEldqW0jm2ioMtEkC3iYHNafElT7K4530tMnr7W3QJHg8JFKdrXGNB8E3BPhhm_AGhzU21LyTTm8KTHIsFcAZLs_-__ZX5A5IbXx2Mj59Tu7id5elzwektVqu9Qtw8FbyZSVJlFzftvD-ASLiZlM
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Optimization+of+a+Self-microemulsifying+Drug+Delivery+System+for+Oral+Administration+of+the+Lipophilic+Drug%2C+Resveratrol%3A+Enhanced+Intestinal+Permeability+in+Rat&rft.jtitle=Advanced+pharmaceutical+bulletin&rft.au=Mirzaeei%2C+Shahla&rft.au=Tahmasebi%2C+Negar&rft.au=Islambulchilar%2C+Ziba&rft.date=2023-07-01&rft.issn=2228-5881&rft.eissn=2251-7308&rft.volume=13&rft.issue=3&rft.spage=521&rft.epage=531&rft_id=info:doi/10.34172%2Fapb.2023.054&rft.externalDBID=n%2Fa&rft.externalDocID=10_34172_apb_2023_054
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2228-5881&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2228-5881&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2228-5881&client=summon